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OBJECTIVES: Recent studies have shown a high prevalence of hypovitaminosis D, defined as a serum
25-hydroxyvitamin D level less than 30 ng/ml, in both healthy populations and patients with chronic kidney
disease. Patients undergoing kidney transplant are at an increased risk of skin cancer and are advised to avoid
sunlight exposure. Therefore, these patients might share two major risk factors for hypovitaminosis D: chronic
kidney disease and low sunlight exposure. This paper describes the prevalence and clinical characteristics of
hypovitaminosis D among patients undergoing kidney transplant.
METHODS: We evaluated 25-hydroxyvitamin D serum levels in a representative sample of patients undergoing
kidney transplant. We sought to determine the prevalence of hypovitaminosis D, compare these patients with a
control group, and identify factors associated with hypovitaminosis D (e.g., sunlight exposure and dietary habits).
RESULTS: Hypovitaminosis D was found in 79% of patients undergoing kidney transplant, and the major asso-
ciated factor was low sunlight exposure. These patients had higher creatinine and intact parathyroid hormone
serum levels, with 25-hydroxyvitamin D being inversely correlated with intact parathyroid hormone serum
levels. Compared with the control group, patients undergoing kidney transplant presented a higher prevalence
of 25-hydroxyvitamin D deficiency and lower serum calcium, phosphate and albumin but higher creatinine and
intact parathyroid hormone levels.
CONCLUSIONS: Our results confirmed the high prevalence of hypovitaminosis D in patients undergoing kidney
transplant. Therapeutic strategies such as moderate sunlight exposure and vitamin D supplementation should
be seriously considered for this population.
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’ INTRODUCTION
Several studies have demonstrated a high prevalence of
hypovitaminosis D (hypo D) in different regions of the world
including Latin America, even though these places receive the
necessary ultraviolet radiation (UVR) required to produce
adequate levels of 25-hydroxyvitamin D [25(OH)D] (1-3).
Recently, vitamin D and its metabolites have been exten-
sively studied because of the role they play in functions such
as the regulation of calcium (Ca) and phosphorus (P) levels,
parathyroid hormone suppression and bone mineralization
in adults (4). In addition, there are associations between
vitamin D deficit and the development of cardiovascular and
immunological disease, cancer, diabetes mellitus and arterial
hypertension (2).
Vitamin D deficiency in patients with chronic kidney
disease (CKD) can lead to alterations in bone mineral meta-
bolism, resulting in frequent fractures and increased cardio-
vascular mortality (4,5). In this context, increases in the
serum levels of 25(OH)D at 10 ng/ml are associated with a
14% decreased mortality risk in this population (5).
Kidney transplant (KT) resolves some of these disorders
and leads to improvements in the prognosis and quality of
life of patients with end-stage renal disease. However,
studies have also shown that hypo D is a persistent event
in during both early and late transplant periods, requiring
supplementation in most cases (4-10). The major causes of
hypo D in patients undergoing KT include: the increased
catabolism of vitamin D secondary to the use of glucocorti-
coids (11), restricted sunlight exposure, and sunscreen use by
medical indication because immunosuppression is associated
with skin cancer in these patients (12).DOI: 10.6061/clinics/2017(07)05
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In addition to the above known effects, Obi et al. showed
that vitamin D deficiency/insufficiency in patients under-
going KT is associated with an increased risk of renal
interstitial fibrosis, renal tubular atrophy, and glomerular
filtration rate (GFR) decline (13). Given the recent develop-
ments of its molecular properties, vitamin D plays a multi-
faceted role and has led us to determine the prevalence and
clinical characteristics of hypo D in a cohort of patients with
KT compared with a control group.
’ PATIENTS AND METHODS
Patients undergoing KT were followed at the Transplant
Unit of Hospital das Clinicas da Faculdade de Medicina da
Universidade de São Paulo. Of these patients, we selected
those who were older than 18 years, showed stable GFR,
and were more than 1 year removed from KT. A total of
752 patients was selected (355 females). In this cohort, we
determined a representative sample size calculation. In
this calculation, we considered a 32.5% prevalence of
25(OH)D deficiency and 5% alpha and a 1% beta risks for
a test power ratio of 99%. The final KT population was
composed of 149 patients; race, gender, age, donor type,
serum creatinine, proteinuria, glutamic-oxaloacetic transami-
nase (GOT), glutamic-pyruvic transaminase (GPT), gamma-
glutamyltransferase (GGT) levels, immunosuppressive therapy,
body mass index (BMI) and vitamin supplementation were
controlled.
Concomitantly, we selected 398 individuals (333 females)
from a sample of 603 volunteering outpatient employees of
the Hospital Universitário da Universidade de São Paulo
and graduate students from the Faculdade de Medicina da
Universidade de São Paulo previously included in Unger
et al. We excluded individuals with diabetes mellitus, arterial
hypertension, serum creatinine levels higher than 1.2 mg/dL
or those on medications/supplements such as Ca, bispho-
sphonates, vitamin D and corticosteroids (see Figure 1) (2).
A blood sample was collected during late winter of 2006,
and serum Ca, P, creatinine, albumin, intact parathyroid hor-
mone (PTHi), total alkaline phosphatase (ALP), 25(OH)D
and BMI were analyzed.
KT recipients were submitted to a single blood collection
during late winter. We chose late winter to coincide with the
period in which samples were collected from the control
group and because it has less UV radiation, enabling us to
detect a greater number of patients with hypo D.
The following parameters were analyzed in the selected
patients: age, gender, race (white or non-white), donor type,
time after KT, immunosuppressive therapy, and post-KT
fractures (spontaneous or minimal trauma). In addition, the
serum concentrations of creatinine, total Ca, P, albumin, ALP,
GOT, GPT, GGT, PTHi and 25(OH)D were measured. The
GFR was estimated using the MDRD simplified formula (14).
The patients completed a questionnaire on dietary food
frequency that evaluated the consumption frequency of major
food sources of vitamin D (e.g., fatty fish and fish oil). Sunlight
exposure habits were analyzed based on the frequency of
exposure (3 or more times a week or less than 3 times a week)
and a sunscreen protection factor (yes or no).
Total serum Ca, serum P, albumin, ALP, GOT and GGT
were determined using routine laboratory techniques. PTHi
was measured using the Immulite analyzer (Diagnostic Pro-
ducts Corporation, Los Angeles, CA, USA; reference range,
10-87 pg/ml). 25(OH)D was measured using a chemilumi-
nescent assay (Dia-Sorin Inc., Stillwater, MN, USA). Serum
concentrations of 25(OH)D between 15 and 30 ng/mL were
considered insufficient, and concentrations less than 15 ng/ml
were considered deficient.
All procedures in this study were performed after appro-
val from the local institutional committee, Comissão de Ética
para Análise de Projetos de Pesquisa (CAPPesq no 1035/07),
and in accordance with the ethical standards of the 1964
Helsinki Declaration.
Statistical analysis
The data are expressed as either means ± SD or medians
and ranges; categorical data are described as percentages.
To determine the relationship between the 25(OH)D levels
and other categorical variables, we used chi-square test and,
when necessary, Fisher’s exact test.
We used the Box and Cox transformation for the variables
age, time after KT, albumin, creatinine, PTHi, GOT, GPT,
GGT and ALP to ensure the normality assumption. Even
with the Box and Cox transformation, the variables age, time
after KT and GOT did not reach normality. Because these
transformed variables presented homoscedasticity (accord-
ing to Levene’s test), they were also considered normally
distributed to compare the serum 25(OH)D levels.
Figure 1 - Participant data. KT: kidney transplant; GFR: glomerular filtration rate; 25(OH)D: 25 hydroxyvitamin D; Ca: calcium;
P: phosphorus; PTHi: intact parathyroid hormone; ALP: alkaline phosphatase; GOT: glutamic-oxaloacetic transaminase; GPT: glutamic-
pyruvic transaminase; GGT: gamma-glutamyltransferase.
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An ANOVA was used to determine the relationship
between the clinical and biochemical variables and serum
25(OH)D (deficient, insufficient or normal). If results were
significant, then we applied the Bonferroni post hoc test. The
correlation between the 25(OH)D levels and other biochem-
ical parameters was analyzed using Spearman’s correlation
coefficients.
The patients undergoing KTand the control group differed
with regard to gender; therefore, we used an ANOVA adjusted
for gender to compare these two groups with regard to BMI,
P, Ca, albumin, creatinine, PTHi, ALP and 25(OH)D for each
variable separately.
The level of significance was set at 5% (p-valueo0.05).
’ RESULTS
Basic characteristics of the patients undergoing KT
Of the 149 patients undergoing KT, 56.4% were female,
and 68.4% were white. The median age was 44 (18 - 81) years,
and the median time after KT of was 6 (1 - 36) years. Approx-
imately 55% of these patients received a graft from a living
donor.
Regarding their 25(OH)D serum levels, 56 (37.5%) patients
presented deficiency, 62 (41.6%) insufficiency, and only 31
(20.8%) a normal concentration. Thus, the prevalence of hypo
D in the study sample was 79.2%.
Post-KT insufficiency fractures (spontaneous or minimal
trauma) were reported in 10% of the patients (N=15). The
mean 25(OH)D serum level was similar between patients
without and those with fractures (21.8±13.2 ng/mL vs.
21.9±8.3 ng/mL). Likewise, we found no differences between
patients with and without fractures regarding the rates of
25(OH)D deficiency or insufficiency.
In addition to the data described above, Table 1 shows the
demographic and biochemical parameters. The patients under
going KT showed serum PTHi above the reference range.
We did not find differences in the 25(OH)D levels (21.1±12.1
vs. 22.6±13.4) between patients with abnormal liver func-
tion (GGT levels450 U/L) and those with preserved liver
function.
Clinical and demographic characteristics according
to the 25(OH)D categories among patients
undergoing KT
Table 2 describes the clinical and demographic character-
istics according to the 25(OH)D categories (deficient, insuffi-
cient and normal). Donor type was associated with important
differences, although they were not significant. Specifically, we
found that 28% of patients who received a graft from a living
related donor had normal 25(OH)D levels, whereas only 12%
of patients receiving a graft from a standard cadaveric donor
showed normal 25(OH)D levels (p=0.055).
Regarding the frequency of sunlight exposure, we observed
a significant difference between those who were exposed to
the sun more than 3 times a week and those who had less
exposure with regard to 25(OH)D levels; specifically, 55.8%
of patients with higher sun exposure had a normal concentra-
tion of 25(OH)D versus 10.4% in the group with lower sun
exposure (po0.0001). The use of sunscreen did not affect the
serum concentrations of this vitamin. We did not find a
significant relationship between 25(OH)D serum levels and
Table 1 - Demographic and biochemical parameters of patients undergoing KT.
Demographic parameters Biochemical parameters Reference range
Gender 25(OH)D (ng/mL) 21.8 ± 12.8
Female 84 (56) 25(OH)D category
Male 65 (44) Normal 31 (21) 430 ng/ml
Race Deficiency 56 (37) o15 ng/ml
White 102 (68) Insufficiency 62 (42) 15 - 30 ng/ml
Non-white 47 (31) PTHi (pg/mL) 80.1 ± 78.3 10 - 87 pg/ml
Time after KT(years) 6 (1 - 36) Ca (mg/dL) 8.9 ± 0.6 8.7 - 10.3 mg/dL
Age (years) 44 (18 - 81) P (mg/dL) 3.0 ± 0.8 2.5 - 4.5 mg/dL
Type of donor Creatinine (mg/dL) 1.5 (0.6 - 4.5) 0.5 - 1.0 mg/dL
Living related donor 82 (55) Albumin (g/dL) 4.4 (3.4 - 5.5) 3.5 - 5.0 g/dL
Standard cadaveric donor 67 (45) ALP (U/L) 65.8 (29.7 - 364.5) 35 - 100 U/L
Insufficiency fracture after KT 15 (10) GOT (U/L) 23 (6 - 121) 0 - 35 U/L
BMI (kg/m2) 25.4 ± 5.3 GPT (U/L) 10 (3 - 81) 3 - 36 U/L
GGT (U/L) 28 (7 - 704) 5 - 36 U/L
Values are expressed as the mean±SD, median (range) or number of patients (%); KT: kidney transplant; BMI: body mass index; 25(OH)D: 25
hydroxyvitamin D; Ca: calcium; P: phosphorus; PTHi: intact parathyroid hormone; ALP: alkaline phosphatase; GOT: glutamic-oxaloacetic transaminase;
GPT: glutamic-pyruvic transaminase; GGT gamma-glutamyltransferase
Table 2 - Demographic and clinical parameters based on 25(OH)D category among patients undergoing KT.
25(OH)D
levels
Race Gender BMI Type of
donor*
Bone fracture
after KT
Immunosuppressive
therapy
White Non-
White
Female Male Non-
obese
Obese Living
donor
Cadaveric
donor
No Yes CNI use CNI
non-use
Deficient 35 (34.3) 21 (44.7) 30 (35.7) 26 (40) 29 (36.7) 27 (38.6) 28 (34.1) 28 (41.8) 52 (38.8) 4 (26.6) 44 (41.1) 12 (28.6)
Insufficient 43 (42.1) 19 (40.4) 35 (41.6) 27 (41.5) 34 (43) 28 (40) 31 (37.8) 31 (46.3) 53 (39.5) 9 (60) 43 (40.2) 19 (45.2)
Normal 24 (23.5) 7 (14.8) 19 (22.6) 12 (18.5) 16 (20.2) 15 (21.4) 23 (28) 8 (12) 29 (21.6) 2 (13.3) 20 (18.7) 11 (26.2)
Total 102 (100) 47 (100) 84 (100) 65 (100) 79 (100) 70 (100) 82 (100) 67 (100) 134 (100) 15 (100) 107 (100) 42 (100)
Values are expressed as number of patients (%); 25(OH)D: 25 hydroxyvitamin D; BMI: body mass index; KT: kidney transplant; CNI: calcineurin inhibitor.
* Chi-square test: p=0.055.
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consumption of food sources of vitamin D. The data are
shown in Table 3.
Biochemical parameters by 25(OH)D category
among patients undergoing KT
Table 4 compares the biochemical parameters across
25(OH)D categories. The results revealed that only serum
creatinine and PTHi significantly differed with regard to
25(OH)D levels. Specifically, we found lower serum levels of
creatinine and PTHi among patients with normal 25(OH)D.
Comparison of the demographic and biochemical
parameters between the control group and
patients undergoing KT
Table 5 shows that the control group and patients under-
going KT had different distributions based on gender. Regard-
ing the biochemical data, we found significant differences
in creatinine, albumin, Ca, P and PTHi between men and
women. As expected, patients undergoing KT showed higher
levels of creatinine and PTHi as well as lower levels of P than
the control group.
However, patients undergoing KT presented lower levels
of this hormone, regardless of 25(OH)D category, when
compared to the control group ( p=0.001); these data are
shown in Table 6.
We analyzed the correlations between the serum 25(OH)D
levels and biochemical parameters but found only one nega-
tive correlation with regard to serum PTHi levels (r=-0.24;
po0.03).
’ DISCUSSION
Despite the growing interest in vitamin D status and its
supplementation forms in both the normal population and
patients with CKD, a lack of data remains regarding vitamin
D levels in KT recipients. Little research has compared the
25(OH)D serum levels between patients undergoing KT
and the healthy population. Our findings coincide with
those of Ebbert et al., who analyzed a pediatric population,
Table 4 - Biochemical parameters of patients undergoing KT according to 25(OH)D category.
Deficient Insufficient Normal p
53 60 31
Creatinine (mg/dL) 2.0 ± 0.9 1.7 ± 0.7 1.5 ± 0.5 0.013*
1.7 (1.0 - 4.5) 1.5 (0.6 - 4.1) 1.3 (1.0 - 2.7)
52 60 31
Albumin (g/dL) 4.4 ± 0.5 4.4 ± 0.3 4.4 ± 0.4 0.660
4.4 (3.4 - 5.3) 4.4 (3.8 - 5.2) 4.5 (3.4 - 5.5)
51 59 31
Ca (mg/dL) 8.9 ± 0.7 8.9 ± 0.5 8.9 ± 0.5 0.997
9.0 (7.0 - 10.2) 8.9 (7.8 - 9.9) 8.8 (7.8 - 10.1)
55 61 31
P (mg/dL) 3.0 ± 0.8 3.0 ± 0.8 2.7 ± 0.6 0.154
2.9 (1.2 - 5.4) 2.9 (1.3 - 5.3) 2.7 (1.2 - 3.8)
55 61 31
PTHi (pg/dL) 104.7 ± 104.6 72.5 ± 58.6 51.6 ± 37.0 0.011*
68.6 (18.2 - 562.5) 53.2 (9.5 - 277.0) 44.1 (13.3 - 229.8)
53 60 31
ALP (U/L) 82.8 ± 54.5 71.6 ± 30.3 65.8 ± 23.4 0.441
69.6 (29.7 - 364.5) 64.8 (34.2 - 191.0) 65.6 (34.5 - 166.4)
52 60 31
GOT (U/L) 27.9 ± 22.8 27.8 ± 11.7 23.5 ± 12.2 0.445
21 (6 - 121) 25 (9 - 64) 19 (13 - 67)
53 60 31
GPT (U/L) 14.2 ± 13.2 13.3 ± 8.5 13.2 ± 14.2 0.387
10.0 (4 - 81) 10.5 (3 - 44) 9.0 (4 - 77)
51 58 31
GGT (U/L) 67.5 ± 116.9 44.1 ± 50.1 35.6 ± 37.2 0.324
31 (7 - 704) 28 (10 - 334) 22 (12 - 206)
Values are expressed as number of patients, mean±SD and median (range). KT: kidney transplant; 25(OH)D: 25 hydroxyvitamin D; Ca: calcium;
P: phosphorus; PTHi: intact parathyroid hormone; ALP: alkaline phosphatase; GOT: glutamic-oxaloacetic transaminase; GPT: glutamic-pyruvic
transaminase; GGT: gamma-glutamyltransferase. *Bonferroni’s post-hoc test: po0.05, Normal vs. Deficient or Insufficient.
Table 3 - Sunlight exposure habits and vitamin D food source consumption frequency according to 25(OH)D category in patients
undergoing KT.
25(OH)D levels Sunlight exposure* Use of sunscreen Vitamin D food source
3 or more
times a week
Fewer than
3 times a week
Yes No Frequent Infrequent
Deficient 2 (5.8) 51 (44.3) 16 (37.2) 40 (38) 5 (27.7) 48 (37.2)
Insufficient 13 (38.2) 52 (45.2) 14 (32.5) 47 (44.7) 6 (33.3) 57 (44.2)
Normal 19 (55.8) 12 (10.4) 13 (30.2) 18 (17.1) 7 (38.8) 24 (18.6)
Total 34 (100) 115 (100) 43 (100) 105 (100) 18 (100) 129 (100)
Values are expressed as number of patients (%); KT: kidney transplant; 25(OH)D: 25 hydroxyvitamin D; * Chi-square test: po0.0001.
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reporting the presence of hypo D in patients undergoing
KT as well as control groups (15). However, our findings
showed that patients undergoing KT had a higher prevalence
of deficiency.
The current study demonstrated that 79% of patients
undergoing KT at the Hospital das Clinicas da Faculdade de
Medicina da Universidade de São Paulo presented with an
insufficiency or deficiency of 25(OH)D during late winter.
These results are similar to those obtained in other studies
conducted throughout the world and across climatic seasons,
revealing a total approximate prevalence of 76-97% (7-10).
Stavroulopoulos et al. analyzed patients undergoing KT
during the summer and winter and confirmed that levels
of 25(OH)D are lower during winter (7). That study explains
why the current evaluation was performed during late
winter, i.e., to detect the highest possible number of patients
with hypo D. Researchers who plan future studies on
vitamin D and clinicians who monitor and manage vitamin D
deficiencies in patients undergoing KT must consider this
seasonal variation.
Nutritional status did not affect serum 25(OH)D levels,
and in contrast to other published data, we did not find a
higher prevalence of hypo D in obese patients, even though
the bioavailability of vitamin D can be influenced by its
storage in adipocytes (16,17).
Hypo D is one of the major causes of secondary hyper-
parathyroidism (SHPT). Unger et al. showed that healthy
subjects develop SHPT in the context of vitamin D deficiency
during winter but show improvements in summer (2). There-
fore, this seasonal variation in 25(OH)D and PTH is likely a
normal response to physiologically compensate for the drop
in vitamin D levels during winter. Among patients under-
going KT, studies have been conducted during different
periods of the year, making it difficult to know whether they
follow the trend observed in the general population. The
literature commonly describes parathyroid hormone stimu-
lation due to 25(OH)D deficiency during the earliest periods
after KT as a consequence of the high doses of corticosteroids
and persistent elevation of phosphatonins (6,18,19). Some
authors have also found this correlation during later periods
of KT recovery (7,20). We observed the same trends in our
patients, showing a negative correlation between PTHi and
25(OH)D serum levels.
Table 5 - Comparison of demographic and biochemical parameters between the control group and patients undergoing KT.
Control group Patients undergoing KT p
Age N=395 N=149
18 to 30 years 68 (17) 29 (19) 0.078
31 to 50 years 210 (53) 71 (48)
51 to 65 years 97 (25) 46 (31)
More than 65 years 20 (5) 3 (2)
Gender N=398 N=149
Female 333 (84) 84 (56) o0.001
Male 65 (16) 65 (44)
Race N=385 N=149
White 269 (68) 102 (68) 0.151
Non-white 116 (29) 47 (32)
N=348 N=149
BMI (kg/m2) 25.9 ± 4.9 25.4 ± 5.3 0.118
25.2 (16.8 - 56.3) 24.9 (16.4 - 44.0)
N=382 N=145
Creatinine (mg/dL) 0.8 ± 0.1 1.8 ± 0.7 o0.001
0.8 (0.4 - 1.2) 1.5 (0.6 - 4.5)
N=384 N=144
Albumin (g/dL) 4.5 ± 0.3 4.4 ± 0.4 o0.001
4.5 (3.3 - 5.4) 4.4 (3.4 - 5.5)
N=382 N=142
Ca (mg/dL) 9.6 ± 0.5 8.9 ± 0.6 o0.001
9.6 (6.7 - 10.8) 8.9 (7.0 - 10.2)
N=383 N=147
P (mg/dL) 3.8 ± 0.7 3.0 ± 0.8 o0.001
3.8 (1.8 - 7.6) 2.9 (1.2 - 5.4)
N=352 N=148
PTHi (pg/dL) 64.9 ± 24.8 80.1 ± 78.3 o0.001
60.5 (5.0 - 144.0) 53.9 (9.5 - 562.5)
N=398 N=149
25(OH)D (ng/mL) 23.8 ± 10.4 21.8 ± 12.8 0.056
21.6 (6.0 - 64.3) 20.7 (4.0 - 70.5)
N=381 N=145
ALP (U/L) 70.9 ± 26.1 74.4 ± 40.1 0.306
69.0 (24.0 - 369.0) 65.8 (29.7 - 364.5)
Values are expressed as number of patients (%), mean±SD and median (range). KT: kidney transplant; BMI: body mass index; Ca: calcium; P: phosphorus;
PTHi: intact parathyroid hormone; 25(OH)D: 25 hydroxyvitamin D; ALP: alkaline phosphatase.
Table 6 - Patients undergoing KT and the control group
according to 25(OH)D category.
25(OH)D levels Control group Patients undergoing KT p
Deficient 90 (23) 56 (37) 0.001
Insufficient 209 (52) 62 (42)
Normal 99 (25) 31 (21)
Values are expressed as number of patients (%); KT: kidney transplant;
25(OH)D: 25 hydroxyvitamin D.
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In addition, regarding the biochemical associations descri-
bed above in the general population, vitamin D insufficiency
contributes to the development of osteoporosis. Moreover,
adequate supplementation can reduce the fracture risk in
approximately 20% of this population (21). However, the effect
of this hormone on the prevalence of fracture during later
periods of KT is unclear, which suggests that low mineral bone
density and hypo D are multifactorial conditions (7). In this
regard, we found no difference between patients with and
without fracture.
The reasons for hypovitaminosis after KT include low
sunlight exposure and the accelerated catabolism of vitamin
D secondary to glucocorticoids use (22). Exposure to UV-A
and UV-B radiation via sunlight can induce skin cancer
through induced mutations in the DNA structure. This radia-
tion is clearly the most important physical environmental
carcinogen for the development of skin cancer, and non-
melanoma skin cancer (NMSC) is the most common malig-
nancy among patients undergoing KT (23,24). The risk of
developing this complication is associated with the duration
and intensity of immunosuppression and cumulative sun
exposure (18). However, some guidelines suggest that sun-
light exposure for short periods of time is beneficial and does
not increase the risk of skin cancer (25,26).
In this sense, sunlight exposure at least 3 times a week
predicted higher 25(OH)D serum levels in our patients, des-
pite the use of sunscreen. However, Penny et al. found an asso-
ciation between low 25(OH)D levels and a high incidence of
NMSC, limiting the use of this therapeutic strategy to low-risk
groups defined by skin type, age, gender and immunosup-
pressive regimen (18,27).
Regarding the effect of immunosuppression on vitamin D
status after KT, steroids accelerate catabolism of vitamin D.
Despite not knowing the steroid doses in our patients, the
development time of transplantation suggests that they recei-
ved a minimal and stable glucocorticoid dose, which most
likely would not explain their vitamin D deficiency. Regard-
ing other immunosuppressive drugs (e.g., calcineurin inhi-
bitors), we similarly did not find an association, contrary to
results reported by Filipov et al. and Eyal et al., who showed
that high tacrolimus doses are associated with hypo D through
hepatic CYP3A4 suppression (28,29).
The potent immunomodulatory activity of 25(OH)D through
the suppression of T cell receptor proliferation and its direct
effect on B cells through the inhibition of immunoglobulin
production are additional physiological effects to consider
among patients undergoing KT (30). Sezer et al. demonstrated
that patients undergoing KT showed an association between
25(OH)D deficit and renal graft failure after one year (31),
whereas other authors have shown a direct relationship
between 25(OH)D deficit and renal graft survival (11,32).
In this respect, our patients presented with an association
between low serum levels of 25(OH)D and higher creatinine
serum levels. In addition to the clinical aspects described
above, Bienaimé et al. found a correlation between vitamin D
status and graft histological findings; specifically, 25(OH)D
serum levels 3 months after transplantation independently
predictor the progression of interstitial fibrosis and tubular
atrophy (IF/TA) at 12 months (32).
Other studies have shown an association between hypo D
and the reception of a renal graft from a cadaver donor (32).
In this regard, although our study was retrospective and did
not evaluate the characteristics of the renal graft, we found a
higher percentage of patients with normal 25(OH)D levels
(28%) in the group receiving a renal graft from a living donor,
compared to only 12% in the group receiving a renal graft
from a cadaveric donor. These results suggest that the immu-
nological tolerance in these patients could be due to the
vitamin D status and that the concentration of this hormone
depends on the type of renal graft received. Specifically,
better compatibility conditions ensure a briefer cold ischemia
time, and a minor ischemia-reperfusion effect predicts higher
deposits of 25(OH)D.
In conclusion, vitamin D deficiency is prevalent among
patients undergoing KT, even in geographic areas with high
UV exposure. Additional studies are needed to clarify the
role that donor type plays in vitamin D deficiency. Further-
more, studies are needed to define the efficacy and safety of
UVR exposure as a therapeutic strategy for these patients.
However, individual sunlight exposure in moderation com-
bined with vitamin D supplementation are the easiest and
safest forms to guarantee adequate levels of 25(OH)D, thereby
leading to the beneficial effects of this hormone.
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